Navigation Links
2008 Lifetime Achievement Award in Heart Failure Presented During HFSA Annual Scientific Meeting
Date:9/22/2008

Heart Failure Society of America Honors Michael R. Bristow, M.D., Ph.D.

TORONTO, Sept. 22 /PRNewswire/ -- The Heart Failure Society of America (HFSA) announced today that Michael Bristow, M.D., Ph.D., Professor of Medicine (Cardiology) and the Co-Director of the University of Colorado Cardiovascular Institute, is the recipient of the Society's 2008 Lifetime Achievement Award. The award was presented to Bristow at the Opening Plenary Session of the HFSA 12th Annual Scientific Meeting, Sept. 21-24, 2008 at the Metro Toronto Convention Centre in Toronto, Ontario, Canada.

"The HFSA's Lifetime Achievement Award is given each year to a clinician or researcher who has advanced the awareness and treatment of heart failure throughout their career," said Dr. Barry Greenberg, HFSA President, and Professor of Medicine, and Director, Advanced Heart Failure Treatment Program, University of California, San Diego. "Dr. Bristow has made many significant contributions to the field of heart failure and we are honored to present him with this award."

Dr. Bristow received his MD in 1970 from the University of Illinois in Chicago, where he also earned a PhD in pharmacology the following year. After completing an NIH postdoctoral fellowship in pharmacology at the University of Illinois, he received his medical training at Stanford University, including an internship in internal medicine, a research fellowship in medicine/oncology, and a residency in medicine. He remained at Stanford to complete a fellowship in cardiology, where he joined the Cardiology faculty in 1979. He moved to the University of Utah in 1984, where he co-founded the first multi-hospital heart transplant program in the U.S. Dr. Bristow is board certified in internal medicine and in the subspecialty of cardiovascular diseases.

Dr. Bristow has authored more than 350 peer-reviewed papers and book chapters on heart failure and other cardiovascular diseases. He was instrumental in elucidating key molecular mechanisms underlying heart failure and the use of beta-blockers for its treatment, and in developing the first pharmacogenetically targeted cardiovascular drug (bucindolol, Gencaro(TM)), currently under consideration for FDA approval.

He has received many academic and industry honors, including the Therapeutic Frontiers Award, presented by the American College of Clinical Pharmacy, for development of beta-blockade as a treatment for chronic heart failure, and in 2008 the Pharmaceutical Research and Manufacturers of America Clinical Trial Exceptional Service Award for the development of carvedilol for heart failure. In 1999, he was ranked by Science Watch, as first among heart failure investigators in impact of cardiovascular publications between 1993 and 1997, and he is an original member (2002) of the Institute of Scientific Information's Highly Cited Researchers.

The purpose of the HFSA Lifetime Achievement Award, to be given at the HFSA Annual Scientific Meeting, is to recognize an individual who has made a significant and sustained contribution to the field of heart failure in terms of its scientific understanding, epidemiology or clinical care, or for his or her exemplary leadership or inspiration to others resulting in an important impact on the field.

About Heart Failure

Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured from heart attack or high blood pressure and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects from 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggest the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit http://www.abouthf.org.

About the Heart Failure Society of America

The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,700 members and provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at http://www.hfsa.org.


'/>"/>
SOURCE The Heart Failure Society of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Reid Supply Introduces Lifetime Warranty on New Line of Hand Tools
2. Seniors Gain Experiences of a Lifetime
3. Individual Genome Changes Over a Lifetime
4. New PurinaCare(TM) Pet Health Insurance Helps Offer Dogs and Cats a Lifetime of Health and Happiness
5. Lifetime Medical Organizer
6. After Collecting 22 Million Petition Signatures on myLifetime.com, Bipartisan Breast Cancer Patient Protection Act Gets First Congressional Hearing in 12 Years
7. Familial Breast Cancer Risk Lasts a Lifetime for Sisters
8. Lifetime Television Proudly Announces October Marquee Event Original Movie, Living Proof Starring Emmy(R) and Grammy(R) Award Winner Harry Connick, Jr.
9. NAMI: Women and Depression; 1 in 8 in Their Lifetime; Twice the Rate of Men
10. African Journey of a Lifetime With Alicia Keys! - Documentary Follows Keep a Child Alives Outreach to Communities Affected With HIV/AIDS
11. AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: